Ken Song is the founder of Ablaze Pharmaceuticals. Ablaze Pharmaceuticals has raised $75M in total funding. Latest round: Series A. Based in Shanghai, China.
Ken Song is a co-founder and Chairman of the Board of Ablaze Pharmaceuticals, a clinical-stage pharmaceutical company established in 2021. Ablaze Pharmaceuticals focuses on developing and commercializing innovative targeted radiopharmaceutical therapies (TRT) for cancer patients in the greater China market. The company launched with a $75 million Series A financing round.
Full founder directory · Investor directory · Company funding database · Fundraising library